Bio-Pharm Archives - 17 중 14 번째 페이지

Celltrion Signs Contract with Major U.S. Insurer Cigna to List 'Zymfentra'

Celltrion has signed a listing agreement for Zymfentra with the major U.S. insurer Cigna, following its successful agreements with the three largest Pharmacy Benefit Managers (PBMs) just five months after…

Cheon Okhyeon

2024-08-29

"Cosmetic Segment Expected to Lead Medical Device Industry in H2"

There is a growing consensus that aesthetic-focused companies, which demonstrated strong stock performance in Q2, will drive growth in the healthcare and medical device industries in the second half of…

Jang Jawon

2024-08-28

Voronoi's Global Licensing Deal Sparks Optimism for "Continued Success"

Voronoi, a drug development specialist that recently licensed out its autoimmune disease treatment pipeline to a U.S. pharmaceutical company, is expected to maintain its competitive edge in the global market,…

Jang Jawon

2024-08-27

Who Led LECLAZA-RYBREVANT Combination Therapy Clinical Trial and Achieved FDA Approval?

"When coincidences accumulate, they become inevitable. The fact that LECLAZA, which I once crossed paths with, came back to me, and the timing of developing LECLAZA and RYBREVANT together—everything fell…

Cheon Okhyeon

2024-08-21

Celltrion Receives FDA Approval for Phase 3 Clinical Trial of Keytruda Biosimilar in the U.S.

Celltrion announced on the 12th that it has received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 Investigational New Drug (IND) application for 'CT-P51', a…

Cheon Okhyeon

2024-08-13

Nabota Drives Daewoong Pharmaceutical to Record Breaking Q2 Results

Daewoong Pharmaceutical achieved its highest-ever quarterly performance in Q2, driven by a focus on new drugs and an increased share of in-house products. On August 9, Daewoong announced that it…

Cheon Okhyeon

2024-08-09

"Hugel's Record-Breaking Performance Driven by Expanded Exports to China and Europe"

Market expectations are rising for Hugel following its announcement of results that far exceeded projections. Analysts predict that the company's strong performance will continue in the second half of the…

Jang Jawon

2024-08-08

GC's Struggles in Q2, Reversal Expected in H2?

There is a prediction in the securities industry that GC, which showed poor performance in Q2 this year, will succeed in turning the atmosphere around in the second half. It…

Jang Jawon

2024-08-06

Celltrion's 'Zymfentra' Listed by Big Three PBMs

Celltrion's 'Zymfentra', has been successfully listed in the formularies of all three major Pharmacy Benefit Managers (or PBMs) in the United States. On August 5, Celltrion announced on its website…

Cheon Okhyeon

2024-08-05

Weight Loss of Over 20% with Obesity Drug 'Mounjaro' Approved in South Korea

The obesity treatment drug 'Mounjaro' (active ingredient: tirzepatide), which has shown powerful weight loss effects exceeding 20%, has been approved in South Korea. This medication, gaining sensational popularity in the…

Won Jonghyuck

2024-08-01